Fiche centre
Johns Hopkins University
Baltimore — United States
Essais liés28clinical trials
VilleBaltimorelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04259255
Essais cliniques associés
28| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | Épilepsie | À vérifier | NCT02694094 | Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy | ACTIVE_NOT_RECRUITING |
| CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis | SEP | À vérifier | NCT04495556 | CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT04261790 | Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT05151471 | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| Belimumab | SEP | Phase 2 | NCT04767698 | Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis | TERMINATED |
| Intravenously administered pooled human immunoglobulin (IVIG) | Myopathies | Phase 2 | NCT06599697 | The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| Edaravone (Radicava®/Radicava ORS®) | Sclérose latérale amyotrophique | À vérifier | NCT04259255 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) | COMPLETED |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| Adalimumab | Parkinson | Phase 2 | NCT06996652 | PRISMS — An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04165824 | Safety Study of Oral Edaravone Administered in Subjects With ALS | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04577404 | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED |
| ION363 | Sclérose latérale amyotrophique | Phase 3 | NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) | ACTIVE_NOT_RECRUITING |
| XT-150 | Sclérose latérale amyotrophique | Phase 1 | NCT06704347 | Safety Study of XT-150 in Participants With ALS | NOT_YET_RECRUITING |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Sclérose latérale amyotrophique | À vérifier | NCT04363684 | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | RECRUITING |
| Pridopidine | Sclérose latérale amyotrophique | Phase 3 | NCT07322003 | PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | RECRUITING |
| Histotripsie — HistoSonics Edison System | Cancer | Non applicable | NCT05820087 | The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) | ACTIVE_NOT_RECRUITING |
| Focal cortical cooling | Épilepsie | Non applicable | NCT06391294 | Neuronal and Network Mechanisms of Electrocortical Stimulation | ENROLLING_BY_INVITATION |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06309966 | RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| Ublituximab | SEP | Phase 4 | NCT07389590 | Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis | RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |
| Ocrelizumab | SEP | Phase 4 | NCT03853746 | Short-term B-cell Depletion in Relapsing Multiple Sclerosis | COMPLETED |
| Living With Frontotemporal Dementia | Alzheimer | À vérifier | NCT01738386 | Living With Frontotemporal Dementia | TERMINATED |
| Ocrelizumab | SEP | À vérifier | NCT03873389 | Ocrelizumab Effects on the Metabolome in MS | COMPLETED |
| Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia | Alzheimer | NA | NCT02675270 | Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia | COMPLETED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |